EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current and Future Perspectives of Adjuvant Therapy for Resected Colorectal Liver Metastases

Kozo Kataoka iD, Kei Kimura iD, Ayako Imada, Kazuma Ito iD, Zhenxin Rao, Yuko Fukumoto, Jihyung Song, Yuki Horio iD, Ryuichi Kuwahara, Motoi Uchino iD, Takayuki Yoshino, Eiji Oki iD und 2 weitere

Cancers · 08.04.2026 · 18 (8) · 1188

DOI: 10.3390/cancers18081188 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 08.04.2026. Verfasst von Kozo Kataoka und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Lower GI Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya 663-8131, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hyogo Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The liver is the most common site of metastatic disease in patients with colorectal cancer. However, the multidisciplinary management of colorectal liver metastases (CLMs) remains suboptimal. Over the past several decades, numerous randomized trials have evaluated the efficacy of adjuvant chemotherapy following CLM resection, revealing improvements in disease-free survival. Nevertheless, these studies have not consistently demonstrated benefits in overall survival, resulting in controversy with regard to the role of routine postoperative chemotherapy. Circulating tumor DNA (ctDNA) has recently emerged as a promising biomarker for detecting molecular residual disease after surgery. Multiple studies have consistently shown that postoperative ctDNA positivity is strongly associated with inferior recurrence-free survival and overall survival in patients with colorectal cancer. In addition to its prognostic value, ctDNA may also assist in guiding postoperative therapeutic decisions. In prospective observational studies of CLM, adjuvant chemotherapy provided potential clinical benefits primarily in patients with ctDNA-positive disease, whereas limited benefits were observed in ctDNA-negative patients. These findings suggest that ctDNA-based detection of molecular residual disease may aid in developing a framework for risk-adapted postoperative management after CLM resection. However, several challenges remain, including the identification of an optimal treatment regimen for ctDNA-positive patients and the improvement of ctDNA assay sensitivity. Ongoing biomarker-driven clinical trials may clarify whether ctDNA-guided strategies can improve patient selection and clinical outcomes following curative resection of CLM.

Schlagwörter

Stichwörter der Autor:innen

adjuvant therapycirculating tumor DNAcolorectal liver metastases

Autor:innen und Institutionen

  • Division of Lower GI Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya 663-8131, Japan.
  • Division of Inflammatory Bowel Disease Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Nishinomiya 663-8131, Japan.
  • Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan.
  • Department of Advanced Medicine and Innovative Technology, Kyushu University Hospital, Fukuoka 812-8582, Japan.
  • Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan.

ORCID-Profile: Kozo Kataoka, Kei Kimura, Kazuma Ito, Yuki Horio, Motoi Uchino, Eiji Oki

Förderung

  • Hyogo Medical University

Zitieren

APA

Kataoka, K., Kimura, K., Imada, A., Ito, K., Rao, Z., Fukumoto, Y., Song, J., Horio, Y., Kuwahara, R., Uchino, M., Yoshino, T., Oki, E., Kanemitsu, Y., & Ikeda, M. (2026). Current and Future Perspectives of Adjuvant Therapy for Resected Colorectal Liver Metastases. Cancers, 18(8), 1188. https://doi.org/10.3390/cancers18081188

Vancouver

Kataoka K, Kimura K, Imada A, Ito K, Rao Z, Fukumoto Y, et al. Current and Future Perspectives of Adjuvant Therapy for Resected Colorectal Liver Metastases. Cancers. 2026;18(8):1188. doi:10.3390/cancers18081188

BibTeX
@article{Kataoka2026,
  author = {Kataoka, Kozo and Kimura, Kei and Imada, Ayako and Ito, Kazuma and Rao, Zhenxin and Fukumoto, Yuko and Song, Jihyung and Horio, Yuki and Kuwahara, Ryuichi and Uchino, Motoi and Yoshino, Takayuki and Oki, Eiji and Kanemitsu, Yukihide and Ikeda, Masataka},
  title = {Current and Future Perspectives of Adjuvant Therapy for Resected Colorectal Liver Metastases},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {8},
  pages = {1188},
  doi = {10.3390/cancers18081188}
}
Kostenlos starten →